US 11,701,403 B2
Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS)
Aldo Iacono, Cockeysville, MD (US); Oliver Denk, Muensing (DE); and Gerhard Boerner, Utting (DE)
Filed by Breath Therapeutics GmbH, Munich (DE)
Filed on Sep. 26, 2022, as Appl. No. 17/935,140.
Application 17/935,140 is a continuation of application No. 17/046,307, granted, now 11,484,566, previously published as PCT/EP2019/058958, filed on Apr. 9, 2019.
Claims priority of provisional application 62/656,226, filed on Apr. 11, 2018.
Claims priority of application No. 18172067 (EP), filed on May 14, 2018.
Prior Publication US 2023/0128855 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/13 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/13 (2013.01) [A61K 9/0078 (2013.01); A61P 11/00 (2018.01); A61K 45/06 (2013.01)] 32 Claims
 
1. A method for treating bronchiolitis obliterans syndrome (BOS) in a double lung transplanted patient, or delaying the progression of BOS in a double lung transplanted patient being diagnosed with BOS, the method comprising the steps of
(a) identifying a patient who has received a double lung transplant and is at risk to develop or subsequently has developed BOS; and
(b) administering to said patient a therapeutically effective dose of aerosolised liposomal cyclosporin A (L-CsA) by inhalation
wherein the progression of BOS of the double lung transplanted patient being diagnosed with BOS is reduced to a level of up to 20% decline of the forced expiratory volume in one second (FEV1) of said patient compared to FEV1-value at the beginning of the treatment.